TwinStrand Biosciences v. Guardant Health: Federal Circuit Appeal Dismissed
TwinStrand Biosciences and Guardant Health jointly agreed to dismiss a Federal Circuit appeal in a patentability dispute over US11149306B2, covering methods and systems for detecting genetic variants. The proceeding closed in just 70 days with each side bearing its own costs — no merits ruling was issued.
Stipulated Federal Circuit exit: no merits ruling on genetic variant detection patent
TwinStrand Biosciences, Inc., a Seattle-based genomics company and holder of US11149306B2, brought a patentability dispute against Guardant Health, Inc., a leading liquid biopsy and circulating-tumour DNA diagnostics company. The underlying proceeding concerned an invalidity or cancellation action targeting claims in US11149306B2, which covers methods and systems for detecting genetic variants — technology directly relevant to error-corrected next-generation sequencing platforms used in cancer diagnostics.
The Federal Circuit appeal, docketed on 1 April 2024, was terminated on 10 June 2024 via a joint stipulation of dismissal entered under Fed. R. App. P. 42(b). The court ordered the proceeding dismissed and directed each party to bear its own costs. Because the dismissal was by agreement and no merits briefing had concluded, the Federal Circuit issued no ruling on the underlying patentability question — leaving the validity status of US11149306B2 unresolved by this appeal.
A 70-day lifespan from filing to closure is notably short for a Federal Circuit appeal and strongly suggests the parties reached a resolution — or at minimum a strategic truce — outside the appellate proceedings. The cost-neutral order is consistent with a negotiated settlement or a decision by one party to abandon the appeal rather than litigate to judgment. The public record does not disclose the underlying commercial terms, if any, that prompted the stipulation, leaving the true driver of dismissal uncertain.
Filing to Appeal Dismissed in 70 days
70 days — resolved before any merits briefing cycle could complete
Appeal dismissed by stipulation: what FRAP 42(b) means for both parties
FRAP 42(b) dismissal: no merits ruling, appeal ends by agreement
Fed. R. App. P. 42(b) allows parties to voluntarily dismiss an appeal by stipulation. The Federal Circuit issued no opinion on the patentability of US11149306B2 — whatever decision sat below (likely a PTAB outcome) remains the operative ruling unless separately challenged. The dismissal is procedural, not substantive.
Procedural exit — no appellate meritsTwinStrand exits with no adverse Federal Circuit ruling
Because no merits decision was entered, TwinStrand avoids any precedential Federal Circuit finding against US11149306B2. If the underlying PTAB or district court proceeding produced an unfavourable result, the dismissal stops the record there — but also prevents TwinStrand from obtaining an appellate reversal. The patent’s enforceability is governed solely by the pre-appeal ruling.
No new adverse ruling for patent holderGuardant Health avoids appellate scrutiny of the invalidity record
Guardant Health benefits from the absence of any Federal Circuit ruling that could have clarified or strengthened the patent’s validity. If the underlying proceeding favoured Guardant, that result stands unchallenged. Each side bearing its own costs is consistent with a negotiated resolution rather than a clear winner — though the public record does not disclose any settlement terms.
Underlying result preserved; no costs awardedGenetic variant detection patent landscape remains unsettled
The stipulated dismissal leaves unresolved whether US11149306B2’s claims survive invalidity scrutiny at the appellate level. Competitors and product teams in error-corrected sequencing and liquid biopsy diagnostics cannot rely on this proceeding to inform FTO analysis. The patent’s claim scope and enforceability must be assessed against the pre-appeal record only, heightening due-diligence obligations for the sector.
FTO uncertainty remains for diagnostics sectorFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | TWINSTRAND BIOSCIENCES, INC. | Company | Genomics technology company — holder of US11149306B2 (genetic variant detection)Search in Eureka ↗ |
| Defendant | Guardant Health, Inc. | Company | Liquid biopsy and circulating tumour DNA diagnostics companySearch in Eureka ↗ |
| Plaintiff counsel | Christopher Michael Gallo | Attorney | Counsel for TWINSTRAND BIOSCIENCES, INC.Search in Eureka ↗ |
| Plaintiff counsel | David Holman Esq. | Attorney | Counsel for TWINSTRAND BIOSCIENCES, INC.Search in Eureka ↗ |
| Plaintiff counsel | Ralph Wilson Powers III | Attorney | Counsel for TWINSTRAND BIOSCIENCES, INC.Search in Eureka ↗ |
| Plaintiff counsel | Richard Crudo | Attorney | Counsel for TWINSTRAND BIOSCIENCES, INC.Search in Eureka ↗ |
| Plaintiff law firm | Sterne, Kessler, Goldstein & Fox, PLLC | Law Firm | Representing TWINSTRAND BIOSCIENCES, INC.Search in Eureka ↗ |
| Defendant counsel | Jad Allen Mills | Attorney | Counsel for Guardant Health, Inc.Search in Eureka ↗ |
| Defendant counsel | Michael T. Rosato | Attorney | Counsel for Guardant Health, Inc.Search in Eureka ↗ |
| Defendant counsel | Richard Torczon | Attorney | Counsel for Guardant Health, Inc.Search in Eureka ↗ |
| Defendant counsel | Sonja Rochelle Gerrard Ph.D. | Attorney | Counsel for Guardant Health, Inc.Search in Eureka ↗ |
| Defendant law firm | WilsonSonsini Goodrich & Rosati LLP | Law Firm | Representing Guardant Health, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The stipulated order is terse by design: it records mutual agreement under FRAP 42(b) and a cost-neutral outcome, but says nothing about the merits of the patentability dispute. Because dismissal is by consent, the Federal Circuit applied no standard of review and made no legal findings. The operative effect is that the pre-appeal tribunal’s record — almost certainly a PTAB decision — remains the last authoritative word on US11149306B2’s validity. Neither party is estopped by a Federal Circuit holding, and no precedent was created for the broader genetic variant detection patent landscape.
US11149306B2 — methods and systems for detecting genetic variants
US11149306B2 (application number US16/945124) claims methods and systems for detecting genetic variants — a technology area central to error-corrected next-generation sequencing, including duplex sequencing approaches that use paired-strand consensus calling to suppress sequencing artefacts. The patent is held by TwinStrand Biosciences, whose core platform is built on duplex sequencing, a high-accuracy variant detection methodology with applications in minimal residual disease monitoring, mutagenicity testing, and liquid biopsy cancer diagnostics.
The commercial stakes of US11149306B2 are significant: Guardant Health’s liquid biopsy franchise — including Guardant360 and Shield — depends on high-sensitivity ctDNA variant detection, the same technical space the patent addresses. A validity challenge against this patent is consistent with a strategy to clear IP barriers ahead of product expansion. The absence of a Federal Circuit ruling leaves the competitive IP boundary between duplex sequencing innovators and ctDNA diagnostic companies unresolved, elevating risk for all players developing error-corrected variant calling pipelines.
Should your team run an FTO against US11149306B2?
Any organisation developing or commercialising methods for detecting low-frequency genetic variants — particularly those using paired-end sequencing, consensus read generation, or error-suppression algorithms in liquid biopsy or NGS workflows — should assess exposure to US11149306B2. The patent’s validity was challenged but never invalidated by an appellate court, meaning its claims remain presumptively valid and enforceable. Product teams at diagnostics companies, CROs, and sequencing platform vendors should treat this as an active FTO obligation.
PatSnap Eureka’s FTO Search Agent can map US11149306B2’s independent claims against your product’s technical architecture, identify relevant prior art that survived or was not considered in the PTAB proceeding, and surface the full TwinStrand prosecution history to flag claim scope arguments. Eureka also monitors continuation applications stemming from US16/945124, so you receive alerts if TwinStrand pursues broader or narrower claims in the same family.
Run a freedom-to-operate analysis on US11149306B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals in genetic variant detection and NGS patent disputes
Cases involving patentability challenges to next-generation sequencing and liquid biopsy patents before the Federal Circuit, with comparable stipulated or procedural dismissal outcomes.
What this case signals for the genomics diagnostics IP landscape
A 70-day Federal Circuit appeal that ends by stipulation rarely means the dispute is truly over — it means the battlefield has shifted.
Short Federal Circuit timelines signal off-record resolution activity
When a Federal Circuit appeal closes in under 90 days without a merits ruling, it typically signals parallel licensing negotiations, a commercial agreement, or a strategic decision to stand on the lower tribunal’s record. IP teams monitoring TwinStrand or Guardant should watch for downstream licensing disclosures or follow-on PTAB filings.
US11149306B2 remains a live enforcement risk for the liquid biopsy sector
No Federal Circuit opinion means no binding precedent on the validity of US11149306B2’s claims. Companies developing error-corrected next-generation sequencing or ctDNA variant detection products should treat this patent as unresolved and conduct fresh FTO analysis — particularly given TwinStrand’s active prosecution and licensing history in duplex sequencing.
TWINSTRAND v Guardant — key questions answered
The Federal Circuit dismissed the appeal by stipulation under Fed. R. App. P. 42(b) on 10 June 2024, just 70 days after filing. The parties agreed to dismiss with each side bearing its own costs. No merits ruling was issued on the patentability of US11149306B2, leaving the underlying tribunal’s decision as the operative record.
A FRAP 42(b) dismissal is procedural — the Federal Circuit issued no opinion on patentability. US11149306B2 remains presumptively valid. The pre-appeal proceeding (likely a PTAB decision) is the last authoritative ruling on validity. No Federal Circuit estoppel was created, meaning future challenges to the patent are not barred by this dismissal.
US11149306B2 covers methods and systems for detecting genetic variants, associated with TwinStrand Biosciences’ duplex sequencing platform. Guardant Health, a liquid biopsy diagnostics company, filed an invalidity/cancellation action, consistent with a strategy to remove IP barriers in the high-sensitivity ctDNA and variant detection space where both companies operate.
The public record does not disclose any settlement terms. A 70-day stipulated dismissal with a cost-neutral order is consistent with a negotiated resolution, a licensing agreement, or a unilateral decision to abandon the appeal. However, PatSnap cannot confirm the existence or terms of any private agreement based on the available docket information.
TwinStrand Biosciences was represented by Sterne, Kessler, Goldstein & Fox, PLLC, with attorneys Christopher Michael Gallo, David Holman, Ralph Wilson Powers III, and Richard Crudo on record. Guardant Health was represented by Wilson Sonsini Goodrich & Rosati LLP, with Jad Allen Mills, Michael T. Rosato, Richard Torczon, and Sonja Rochelle Gerrard Ph.D. on record.
PatSnap Eureka searches patents and litigation data to answer instantly.